文献速递泌尿生殖技术与安全CTPET

99mTc-HYNIC-PSMA-11全身SPECT/CT:前列腺癌患者中68Ga-PSMA PET/CT的临床可行替代方案

99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer.
PubMed 文献 · Br J Radiol · 2026-01-01

本研究纳入10例前列腺癌患者,比较99mTc-HYNIC-PSMA-11全身SPECT/CT与68Ga-PSMA PET/CT的诊断表现。68Ga-PSMA PET/CT检出64个转移灶,SPECT/CT检出49/64个,敏感度76.6%;两者SUVmax均值相当且呈高度显著正相关(r>0.93;P<.01)。作者认为SPECT/CT诊断表现与PET/CT相当,剂量学有利,可能成为前列腺癌评估的替代工具。

要点

  • 99mTc-HYNIC-PSMA-11 SPECT/CT检出49/64个转移灶,敏感度76.6%,低于68Ga-PSMA PET/CT。
  • 两者SUVmax均值相当且高度显著正相关(r>0.93;P<.01)。
  • 唾液腺、肺、肾、膀胱和肝的平均吸收剂量与99mTc-MDP骨扫描相当。

核心结论

  • 全身99mTc-HYNIC-PSMA-11 SPECT/CT的诊断表现与68Ga-PSMA PET/CT相当,且剂量学有利,提示其在前列腺癌评估中具有潜力。

研究设计与样本

  • 纳入10例前列腺癌患者(平均年龄66.4±9.6岁),先行全身68Ga-PSMA-11 PET/CT,后行系列全身(前位和后位)99mTc-HYNIC-PSMA-11显像,系列显像在10分钟、2小时、4小时、6小时、24小时多个时间点进行,全身SPECT/CT在3小时采集。

关键影像表现/征象

  • 68Ga-PSMA-11 PET/CT共识别64个转移灶,99mTc-HYNIC-PSMA-11 SPECT/CT检出49/64个转移灶。

诊断标准与关键数值

  • 99mTc-HYNIC-PSMA-11 SPECT/CT检测转移灶的敏感度为76.6%(49/64)。
  • 68Ga-PSMA-11 PET/CT与99mTc-HYNIC-PSMA-11的SUVmax均值相当,呈高度显著正相关(r>0.93;P<.01)。
  • 唾液腺、肺、肾、膀胱和肝的平均吸收剂量(mSv/MBq)与99mTc-MDP骨扫描相当。

临床应用与阅片要点

  • 99mTc-PSMA-11 SPECT/CT可能作为评估初始PSMA疾病负荷以及PSMA靶向治疗疗效的替代且具成本效益的工具。

局限性

  • 样本量小(n=10)。
  • 原文结论称其「可能」是替代工具,并指出具有「潜力」,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The diagnostic performance of 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT versus 68Ga-PSMA PET/CT was evaluated in prostate cancer patients.

METHODS: As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n = 10; mean age 66.4 ± 9.6 years) underwent whole-body 68Ga-PSMA-11 PET/CT followed by serial whole-body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole-body imaging was performed at multiple time points of 10 minutes, 2 hours, 4 hours, 6 hours, 24 hours and the whole-body SPECT/CT was acquired at 3 hours. The whole-body SPECT/CT data was analysed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q-Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET/CT. The serial whole-body imaging data were used for estimating the radiation absorbed doses (mSv/MBq) to various organs using the MIRD schema and the OLINDA/EXM software.

RESULTS: 68Ga-PSMA-11 PET/CT identified a total of 64 metastatic lesions, while 99mTc-HYNIC-PSMA-11 SPECT/CT detected 49/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET/CT and 99mTc-HYNIC-PSMA-11 were comparable and a highly significant positive correlation (r > 0.93; P < .01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.

CONCLUSIONS: The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT/CT is fairly comparable to 68Ga-PSMA PET/CT and offers a favourable dosimetry indicating its potential for PCa evaluation.

ADVANCES IN KNOWLEDGE: 99mTc-PSMA-11 SPECT/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Hooda M, Kaur K, Watts A, et al. 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer. Br J Radiol. 2026. PMID: 41818667. doi:10.1093/bjr/tqag052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。